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e.2012.10Abstract Background: There is growing evidence suggesting that obstructive sleep apnea OSA is
linked to the occurrence of cardiovascular disorders. Lack of normal nocturnal dipping of blood
pressure has also been considered a risk factor for the occurrence of cardiovascular disorders.
Non-dipping has been described in patients with OSA and is attributed to autonomic dysfunction.
However, the search for a causal link between OSA and cardiovascular disease is still underway.
Objective: To evaluate the occurrence of non-dipping pattern of nocturnal blood pressure, and the
possible role of oxidative stress and ET-1 precursor in patients with OSA.
Subjects and methods: Thirty eight patients with OSA and fourteen normal control subjects were
enrolled in this study and were subjected to history taking, clinical examination, early morning
blood samplings for the measurement of serum malondialdehyde (MDA) and endothelin 1 precur-
sor (ET-1 precursor). All patients with OSA were subjected to full polysomnographic study and
monitoring of nocturnal blood pressure changes.
Results: Nocturnal blood pressure measurement of all patients revealed that thirty six patients
(94.7%) were non-dippers, 15 patients (39.5%) suffered from ischemic heart disease. Serumnea; BP, blood pressure; ET-
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154 Y.A. Ashram et al.endothelin-1 precursor and serum malondialdehyde levels were signiﬁcantly higher in patients with
OSA than in the control group. The systolic blood pressure measured before sleep was also signif-
icantly higher in patients than in the control group. The Epworth sleepiness scale and the clinical
apnea score were signiﬁcantly higher in patients than in the control group.
Conclusions: The high incidence of non-dipping pattern of nocturnal blood pressure in both nor-
motensive and hypertensive patients with OSA may be considered a warning sign for the occurrence
of cardiovascular complications in these patients. Both increased oxidative stress and ET-1 precur-
sor may be among the causative factors responsible for the high prevalence of the non-dipping pat-
tern through increasing sympathetic nervous system activity.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Obstructive sleep apnea (OSA) syndrome is a sleep breathing
disorder characterized by recurrent airﬂow obstruction caused
by a total or partial collapse of the upper airway during sleep.
It is associated with interruption of normal sleep by repetitive
episodes of complete (apneas) and/or partial (hypopneas) ces-
sations of breathing.1 Such episodes are usually associated
with a decrease in oxygen saturation (SaO2) that is normalized
upon resumption of ventilation.2 Several population-based
studies have established an association between OSA and
hypertension3,4 and OSA is now considered as a new cause
of secondary systemic hypertension.4 There is also growing evi-
dence suggesting that OSA is a risk factor for cardiovascular
disorders5 however, the search for a causal link between
OSA and cardiovascular disease is still underway.
Several studies suggested that the repeated episodes of hy-
poxia-reoxygenation may predispose to the development of
oxidative stress as well as endothelial dysfunction in OSA6,7
which are critical pathways in the pathogenesis of cardiovascu-
lar disease in such patients.8
It has been proposed that vascular endothelial dysfunction
and structural vascular changes have been implicated as early
mechanisms in the pathophysiology of hypertension and car-
diovascular disease in OSA.7 Endothelins are 21-amino acid
vasoconstricting peptides produced primarily in the endothe-
lium and are used as markers of endothelial alterations. Endo-
thelin-1 (ET-1) signals vasoconstriction and inﬂuences local
cellular growth and survival.9 For the biogenesis of ET-1, a
larger precursor peptide (pre-proET-1) is cleaved at two sites
to give rise to ET-1 precursor, which is subsequently cleaved
to generate mature ET-1.10 ET-1 has been implicated in the
development and progression of vascular disorders such as
atherosclerosis and hypertension. The role of ET-1 in the path-
ogenesis of hypertension and cardiovascular disease in OSA
patients has been previously investigated. However, there were
inconclusive results as to whether it has a role in development
of hypertension in such patients. Plasma levels of ET-1 have
been shown to be higher in patients with OSA than healthy
controls in one report,11 while another study showed that plas-
ma ET-1 values of patients with OSA were not elevated com-
pared to controls.12 Such conﬂicting results have underscored
the value of the relatively stable endothelin-1 precursor, (ET-
1 precursor) as a more appropriate marker of endothelial alter-
ation than ET-1 because of its longer half-life.13
The pathophysiologic mechanisms by which intermittent
hypoxia during sleep can lead to daytime hypertension may
be more complex. Besides increase in oxidative stress andendothelial dysfunction there is evidence of increased sympa-
thetic activity.14 Blood pressure (BP) is under circadian diurnal
control and normally declines during sleep, compared to day-
time. Most people present a decline in arterial BP between
10% and 20% during nighttime intervals which is called dipper
pattern.14 A nocturnal BP decrease less than 10% of daytime
BP is deﬁned as ‘‘non-dipping.’’15 It has been suggested that
non-dippers show impairment in the autonomic nervous sys-
tem and have an increased risk of hypertension and cardiovas-
cular diseases.14 Non-dipping has also been described in
patients with OSA.16 It could be possible that the increased
sympathetic activity in OSA could result in non-dipping which
could be one of the mechanisms by which OSA contributes to
increased risk of hypertension and cardiovascular disease.2. Aim of the work
To evaluate the occurrence of non-dipping pattern of noctur-
nal blood pressure, and the possible role of oxidative stress
and ET-1 precursor in patients with OSA
3. Subjects and methods
3.1. Study Population and subjects
This study included 38 patients (22 males and 16 females) with
obstructive sleep apnea hypopnea syndrome (OSA) having a
median age of 53 years, and 14 normal normotensive subjects
serving as the control (10 males and 4 females) with a median
age of 54 years The study protocol was approved by the local
ethics committee, and informed consents were obtained.
3.2. Study measurements
A- All subjects were subjected to the following:
(1) Full history taking including assessment of clinical
apnea score17 which comprises a questionnaire about:
snoring, obesity (assessed by body mass index),18 and
daytime hypersomnolence (assessed by Epworth Sleepi-
ness Scale),19 witnessed apnea by bed partner and sys-
temic hypertension. Also a history of diabetes mellitus
(conﬁrmed by fasting blood glucose measurement),
ischemic heart diseases and arrhythmias were included.
(2) Systemic blood pressure measurements were obtained.20
Daytime hypertension was deﬁned as daytime BP values
P140 mmHg systolic and P90 mmHg diastolic.19
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1). Blood samples were obtained early in the morning
following full polysomnography. The ET-1 precursor
levels in serum were measured by commercially available
enzyme linked immunosorbent assay (ELISA) kits (Bio-
medica Group).21
(4) Serum malondialdehyde (MDA) as a marker for oxida-
tive stress was measured in all subjects. To 0.5 ml serum,
2.5 ml of 20 mg/dl TCA was added, and the tube was left
to stand for 10 min at room temperature. After centrifu-
gation at 3500 rpm for 10 min, the supernatant was dec-
anted and the precipitate was washed once with 0.05 M
sulfuric acid. Then, 2.5 ml of 0.05 M sulfuric acid and
1 ml of 0.67% thiobarbituric acid (TBA) in 2 M sodium
sulfate were added to this precipitate and the tube was
heated in a boiling water bath for 30 min. After cooling,
the resulting chromogen was extracted with 4 ml of n-
butyl alcohol by vigorous shaking. Separation of the
organic phase was facilitated by centrifugation at
3000 rpm for 10 min, and the optical density was mea-
sured at 530 nm. A standard curve was constructed
using different concentrations of 1,1,3,3-tetramethoxy
propane in ethanol. The concentration of MDA in the
sample was determined in nmol/ml.22
B- All patients with OSA were subjected to full polysom-
nography (somnomedic) Level II sleep study23 to
assess the following:
3.2.1. Sleep stages and arousals
Electroencephalogram (EEG) and electrooculogram (EOG)
were used to detect different stages of sleep: 1 – Light sleep
(stage 1 and 2), 2 – Deep sleep (stage 3 and 4), and rapid eye
movement sleep (REM). Scoring of different stages of sleep
was performed according to criteria established by the Ameri-
can Academy of Sleep Medicine24 Total sleep time (TST) and
sleep efﬁciency in addition to the period of each stage and its
percentage in relation to total sleep time were calculated with
assistance of the computer software. Also arousal was scored
if there was abrupt shift of EEG to a lighter stage and/or full
awakenings that lasted at least three seconds with at least 10 s
of stable sleep preceding the change. An arousal index was cal-
culated by dividing the total number of arousals by TST.24
3.2.2. Respiratory events
Monitoring of airﬂow using both thermistor and nasal cannula
connected to the pressure transducer, respiratory effort using
thoracic and abdominal belts, oxygen saturation using ﬁnger
pulse oximeter and the evaluation of snoring using a micro-
phone. Manual scoring was performed for all patients. Apneas
and hypopneas were deﬁned using criteria established by the
American Academy of Sleep Medicine.24 Apnea was consid-
ered when there is drop in the ﬂow excursion by P90% of
the baseline for at least 10 s and hypopnea was deﬁned when
there is drop by P30% of baseline and associated with
P4% desaturation from pre-event baseline for at least 10 s.
Another alternative deﬁnition for hypopnea is a drop in the
ﬂow excursion by P50% of baseline for at least ten seconds
and associated with P3% desaturation from pre-event base-
line and/or arousal. Utilizing these deﬁnitions, an apnea-hypo-
pnea index (AHI) was calculated by dividing the total number
of apneas and hypopneas by the TST.3.2.3. Nocturnal blood pressure monitoring
Electrocardiogram and oximeter were used to detect changes
in blood pressure during sleep using pulse transit time
(PTT). PTT-based method for indirect measurement of blood
pressure was proved to be effective.25 Measurement of blood
pressure before sleep was obtained and blood pressure calibra-
tion was performed before starting manual scoring. The fol-
lowing parameters were measured during sleep: average
systolic blood pressure, maximal blood pressure, time of max-
imal pressure, maximal increase in blood pressure and index of
increase in blood pressure. Difference between systolic BP be-
fore sleep and average systolic BP during sleep was calculated
to detect the level of dipping in systolic BP. Ten percent of the
systolic blood pressure was calculated for each patient and
considered as the minimal value for normal nocturnal dipping
and compared with that actually obtained by the patient dur-
ing sleep (Dipping = pre-sleep systolic BP  average systolic
BP during sleep). Nocturnal hypertension was deﬁned as aver-
age night-time BP valuesP 125 mmHg systolic and
P75 mmHg diastolic.264. Statistical analysis
After data entry into a specially designed sheet using Microsoft
Excel, a print out of the data was thoroughly revised and data
entry mistakes were corrected. Then the ﬁle was transferred
into Statistical Package for Social Science (SPSS) version 17
format and data explore was carried out.
Testing normality using Kolmogorov–Smirnov test proved
that some variables are abnormally distributed, so the median
and inter-quartile range (IQR) was used for descriptive pur-
poses. Non-parametric tests were used for comparison between
the two groups (Mann–Whitney test). Box and Whisker graph
was used to illustrate the minimum, maximum, median and
IQR for the variables. Kendall’s–Tau bivariate correlation
was also performed. Alpha error was set to 5%.5. Results
Out of 38 patients with OSA included in this study three pa-
tients (7.9%) had mild sleep apnea, six patients (15.8%) had
moderate sleep apnea, and 29 patients (76.3%) had severe
sleep apnea. History taking revealed that 15 patients (39.5%)
suffered from ischemic heart disease and fasting blood glucose
measurements revealed that 16 patients (42.1%) were diabet-
ics. Diurnal blood pressure measurement in patients with
OSA revealed that thirty two patients (84.2%) were hyperten-
sive and 6 patients (15.8%) were normotensive, nocturnal
blood pressure measurement of all patients revealed that thirty
six patients (94.7%) were non-dippers and lacked the sleep-re-
lated, nocturnal systolic dipping in blood pressure, while only
two patients of the 38 patients with OSA (5.3%) showed nor-
mal dipping. Thirteen patients of the non-dippers (36.1%)
showed increase rather than decrease in average systolic BP
during sleep than that before sleep. Thirty patients (83.3%)
of the 36 patients with non-dipping pattern of nocturnal blood
pressure also showed systemic hypertension, while the other 6
(16.6%) patients with non-dipping pattern were normotensive.
Fig. 1 shows the comparison between normally expected dip-
ping for the pre-sleep BP and the actual measured dipping in
patients with OSA during sleep. All of the 15 patients with
level of dipping in10% dipping from in
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Figure 1 Boxplots comparing the normal 10% expected decrease
in pre-sleep SBP and the actual degree of change in SBP during
sleep in the 38 patients with OSA. It shows the absence of expected
decrease and even increase rather than decrease in systolic BP
during sleep.
156 Y.A. Ashram et al.ischemic heart disease were non-dippers and 7(46.6%) of them
had an increase rather than a decrease of nocturnal blood pres-
sure 14 of (93.3%) them were hypertensive.
Comparison between the results obtained from patients and
control groups showed that serum pro-endothelin-1 and serum
malondialdehyde levels were signiﬁcantly higher in patients
with OSA than in the control group Z= 2.971, P= 0.003
and Z= 5.468, P< 0.001 respectively. The systolic pressure
measured before sleep was also signiﬁcantly higher in patients
than in the control group Z= 2.60, and P= 0.009. The Ep-
worth sleepiness scale and the clinical apnea score were signif-
icantly higher in patients than in the control group. Z= 5.490,
P< 0.001, Z= 5.736, P< 0.001 respectively (Table 1, Figs. 2
and 3).
Table 2 shows the polysomnographic data of patients with
OSA, and Fig. 4 demonstrates a 5-min fragment from a full
night sleep study recording (polysomnography) of a 51 year
old male patient complaining of excessive daytime sleepiness,
snoring, sense of suffocation and chocking during sleep, unre-
freshing sleep and morning headache. He is normotensive and
non-diabetic. His Epworth sleepiness scale was 22/24 and his
clinical apnea score was 4/5. His BP before sleep was 120/Table 1 Different studied parameters in patients with OSA and co
Variables OSA (n= 38)
Min–Max Me
Age 33–87 53(
Epworth sleepiness scale (/24) 9–24 17(
Clinical apnea score (/5) 2–5 4(1
Systolic BP before sleep (mmHg) 110–220 140
Diastolic BP before sleep(mmHg) 70–140 90(
S. ET-1 precursor-1 (fmol/ml) 0.16–0.48 0.1
S. malondialdehyde (nmol/ml) Min–Max Mean ± SD 3.9–72.8 37.80 mmHg. (case no. 19). The recording shows repetitive
obstructive apneas and hypopneas associated with repetitive
hypoxia-reoxygenation, surges in BP (higher in systolic BP
than diastolic BP), microarousals and increase in sympathova-
gal balance. Monitoring heart rate shows sinus bradytachar-
rhythmias. His polysomnographic study revealed very severe
OSA (AHI = 110.8/h, ODI = 110.4/h). His average BP dur-
ing sleep was 115/86 mmHg with absence of normal dipping
in BP (non-dipper), his maximal systolic BP during sleep was
156/115 mmHg and index of increase in BP was 85.9/h.
Fig. 5 shows the whole night graphics of the full polysomnog-
raphy of the same patient showing the saw tooth pattern of the
oxygen saturation curve characteristic for OSA.
6. Discussion
Blood pressure is under circadian control and normally de-
clines during sleep, compared to daytime. Most people present
a decline in arterial BP between 10% and 20% during night-
time intervals which is called dipper pattern.14 A nocturnal
BP decrease less than 10% of daytime BP is deﬁned as ‘‘non-
dipping.’’15 In the present study the absence of normal dipping
of systolic BP was one of the most prominent features of BP
measurement in patients with OSA. Thirty six patients
(94.7%) lacked the sleep-related, nocturnal decrease, or
‘‘dip’’ in blood pressure seen in normal individuals. Thirteen
patients of the non-dippers (36.1%) showed increase rather
than decrease in average systolic BP during sleep than before
sleep. The incidence of systemic hypertension among non-dip-
pers was 83.3% (30 patients) All normotensive patients with
OSA (6 patients) included in the present study were non-dip-
pers. Only two patients of the 38 patients with OSA (5.3%)
showed normal dipping in their blood pressure during sleep.
Similarly, Loredo et al.27 reported that the incidence of non-
dipping in 44 subjects with sleep apnea, was 84%. Pankow
et al.28 also demonstrated an increased prevalence of hyperten-
sion and non-dipping, in 93 patients with moderate and severe
sleep-disturbed breathing. Hla et al.16 reported a signiﬁcant
longitudinal association between baseline OSA status and the
development of nocturnal BP systolic non-dipping among par-
ticipants who initially had normal nocturnal BP dipping.
These ﬁndings together with our results suggest an associa-
tion between OSA and nocturnal non-dipping which are inter-
esting ﬁndings because previous studies have linked the non-
dipping pattern of nocturnal BP to increased cardiovascular
risk (stroke, myocardial infarction, etc.) and higher cardiovas-
cular mortality in both hypertensive and normotensive non-ntrol subjects.
Control (n= 10) Signiﬁcance (P)
dian (IQR) Min–Max Median (IQR)
19) 45–65 54(5) Z= 0.620 P= 0.536
8) 5–7 5(1) Z= 5.490 P< 0.001*
) 0–2 0(1) Z= 5.736 P< 0.001*
(25) 110–140 130(10) Z= 2.60 P= 0.009*
10) 70–90 80(10) Z= 1.862 P= 0.063*
98(0.02) 0.17–0.19 0.18 (0.01) Z= 2.971 P= 0.003*
3(30.2) 2.2–3.9 3.3(1.1) Z= 5.468 P< 0.0001*
Figure 3 Boxplots for Serum MDA (Malondialdehyde),
(nmol/ml) in patients with OSA and control group.
Table 2 Polysomnographic data for 38 patients with OSA.
Polysomnographic data Min–Max Median (IQR)
Polysomnographic respiratory data
Apnea Hypopnea index
(A + H/h)
12.5–127.5 51.5(41)
Oxygen desaturation index
(OD/h)
2.3–113.1 35(44.2)
Average minimal desaturation
(%)
69–94 87(8)
t90% (%) 0–99 23(57.5)
Polysomnographic dlood pressure data
Average SBP during sleep (mmHg) 102–197 138(30)
Maximal SBP during sleep (mmHg) 134–256 184(48)
Maximal DBP during sleep (mmHg) 80–150 106.5(16)
Maximal increase in BP during sleep
(mmHg)
15–91 34.5(22)
Index of increase in BP during
sleep (/h)
0–111.5 29(39.2)
Level of dipping of BP during sleep
(mmHg)
18 to 27 -2(12)
PolysomnographicsSleep data
Sleep eﬃciency (%) 52.2–99.8 79.5(23.7)
Arousal index (/h) 18.9–78.4 45(23.7)
Figure 2 Boxplots showing Serum ET-1 precursor (endothelin-1
precursor) measured in fmol/ml, in patient with OSA and control
group.
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suffered from ischemic heart disease all of which were non-dip-
pers and 14 of them were hypertensive. Patients with OSA
were found to be at an increased risk for several cardiovascular
diseases.4,31,32 It can therefore be suggested that nocturnal
non-dipping is an early sign in a process linking OSA to car-
diovascular disease possibly via multiple pathways.16,33,34
The exact mechanisms responsible for the non-dipping pat-
tern of nocturnal blood pressure are still not fully elaborated.
Loredo et al.27 investigated a possible association between noc-
turnal non-dipping pattern of BP and the quality of sleep, mea-
sured by the percent of slow wave sleep; percentage of time
awake after sleep onset during the sleep period; sleep efﬁ-
ciency; and arousal index. They found the prevalence of non-
dipping to be high in untreated patients with mild to severe
OSA, nonetheless, there was no relation between the quality
of sleep and nocturnal BP dipping. Sleep quality therefore
did not appear to be related to nocturnal BP dipping in
OSA.27 Recently however, the occurrence of nocturnal non-dipping has been linked to the impaired function of the auto-
nomic nervous system in the form of a decreased vagal tone
and increased sympathetic tone.35 In the present study, besides
the characteristic non-dipping of BP, another feature of noc-
turnal BP in patients with OSA was repetitive increase in BP
during sleep followed by fall in BP to the baseline or at higher
level than the baseline pointing to the possible role of sympa-
thetic activation. Arousals are immediate consequences of
sleep apneas and hypopneas. With each arousal, there is tran-
sient reinstitution of the wakefulness, increased sympathetic
and decreased parasympathetic activity consequently, heart
rate and blood pressure increase.36 It is possible that these re-
peated bouts of sympathetic activation prevent complete nor-
malization of BP in the time between events, causing systolic
BP to fail to fully experience the nocturnal dip typically seen
in persons without OSA.36
Repeated apneic episodes are known to increase oxidative
stress, however, the full consequences of the increased oxida-
tive stress are not clearly elaborated. In the present study, ser-
um malondialdehyde (MDA) was used as a marker of
oxidative stress in OSA.37 Our results demonstrated that
MDA was signiﬁcantly higher in patients with OSA than con-
trol subjects. Oxidative stress in OSA may be linked directly to
intermittent hypoxia in resemblance to ischemia reperfusion
injury. Several studies, particularly ones that involved larger
numbers of patients, were able to demonstrate that OSA is in-
deed associated with increased markers of oxidative stress.38–41
The increased oxidative stress may be one mechanism associat-
ing OSA to hypertension. Oxidative stress can induce the
upregulation of numerous redox-sensitive transcription fac-
tors, and can also induce an increase in angiotensin II; and
plasma endothelin which have been linked to hypertension
by increasing vascular resistance.38,42
Chronic intermittent hypoxia and oxidative stress can also
increase sympathetic activity in patients with OSA by increas-
ing the sensitivity of peripheral chemoreﬂexes.43 Peripheral
Figure 4 A fragment from a full night sleep study recording (polysomnography) of a patient with severe OSA (no. 19). Channels from
top: EEG: electroencephalogram, LOC: left eye electrooculogram, ROC: right eye electrooculogram,; EKG: electrocardiogram, PLM l:
left lower limb periodic limb movement, PLM r: right lower limb periodic limb movement, snoring assessed by microphone, Pressure ﬂow:
Air ﬂow:measured by nasal pressure cannula; Flow Th: Air ﬂow measured by thermistor, Thorax: chest effort measured thoracic belt,
Abdom: Abdominal effort measured Abdominal belts, SaO2: oxygen saturation measured by pulse oximetry. Pulse: pulse rate measured
by oximeter, Pleth: pulse wave of the oximeter, Pos: position of the patient, Systolic: systolic BP, Diasto: diastolic BP, SVB:
sympathovagal Balance. Note the recurrent episodes of cessation (or decrease of the amplitude) of ﬂow with persistent respiratory effort
(obstructive apneas). Each episode is associated with hypoxia, and is terminated by an arousal and subsequent restoration of the patency
of the airway and airﬂow. Apnea is associated with bradycardia and followed by tachycardia and increase in BP.
158 Y.A. Ashram et al.chemoreﬂex and baroreﬂex activity have a direct effect on
efferent sympathetic outﬂow.36,39,44,45
Several studies measured circulating levels of ET-1 in pa-
tients with OSA as a possible link between OSA and hyperten-
sion, however results were contradictory and the exact role of
ET-1 in OSA induced hypertension has not been con-
ﬁrmed.12,46–48 One possible reason for the inconclusive results
of endothelin measurement could be its short half life, only
4 ± 7 min. On the other hand ET-1 precursor has proven tobe a more stable marker of endothelial alteration than ET-1
because of its longer half-life.13 Pre-pro-ET and and ET-1 pre-
cursor are cleaved by ET converting enzymes into ET-1, -2, -3
and -4. These ET isoforms bind with different afﬁnities to
ET(A) and ET(B) receptors in the vascular smooth muscle,
and in turn increase calcium ion, protein kinase C and mito-
gen-activated protein kinase and other signaling pathways of
vascular smooth muscle contraction and cell proliferation.49
In the present study, ET-1 precursor was found to be signiﬁ-
Figure 5 The whole night graphics of the full polysomnography of the patient no. 19 showing the saw tooth pattern of the oxygen
saturation curve (representing the intermittent hypoxemia in the form of repetitive desaturation – reoxygenation) characteristic for
OSAHS. Channels from top: sleep proﬁle represented by the hypnogram, PLM: periodic limb movement events, snoring assessed by
microphone, ﬂow: Air ﬂow, SpO2 events: marking events of decreased saturation, SpO2: oxygen saturation measured by pulse oximetry.
Cardiac events: marking events of arrhythmias, deceleration and/or acceleration in pulse rate as detected by ECG, HR: pulse rate
measured by oximeter, class. PTT: events of decrease in pulse transit time, obstruction; markings for obstructive respiratory events, class.
Systolic: marking events of increasing systolic blood pressure, Arousal class.: marking arousal events, position of the patient, note that the
recurrent episodes of desaturation associating to obstructed events of ﬂow are associated with repetitive cardiac events, bradytachyar-
rhythmias, increase in systolic blood pressure and arousals.
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agreement with our results, Jordan et al.13 found that the
ET-1 precursor, was considerably elevated in untreated pa-
tients with OSA and dropped to normal values after long-term
continuous positive airway pressure depending on compliance.
ET-1 besides being a potent vasoconstrictor has also been
shown to increase sympathetic nervous system activity.45
It could therefore be postulated from the results of the pres-
ent study that the intermittent hypoxia associated with OSA
results in increased oxidative stress, ET-1 levels, measured by
assessing the more stable precursor of endothelin ET-1 precur-
sor. Both oxidative stress and the ET-1 precursor as well as re-
peated arousals have been demonstrated to increase
sympathetic nervous system activity and may therefore con-
tribute to the non-dipping pattern in patients with OSA which
can be a risk factor for the occurrence of cardiovascular dis-
ease in such patients.
In conclusion, the high incidence of non-dipping pattern of
nocturnal blood pressure both in normotensive and hyperten-
sive patients with OSA may be considered a warning sign forthe occurrence of cardiovascular complications in these pa-
tients. Both increased oxidative stress and the ET-1 precursor
and repeated arousals may be among the causative factors
responsible for the high prevalence of non-dipping pattern
through increasing sympathetic nervous system activity.
Screening for non-dipping pattern should be considered as part
of the workup of patients with OSA even if they are normoten-
sive, in addition to hypertensive patients especially those
whose 24 h BP studies that yielded non-dipping should also
be screened for occult OSA as a cause of secondary hyperten-
sion. Early treatment of such patients may cut down the car-
diovascular risk factor.References
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